Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen

Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU.

As a bioequivalent version of Victoza pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA. 

The successful development of Liraglutide highlights Adalvo's capability to offer a diverse and comprehensive diabetes portfolio, encompassing both complex peptide injectables and small molecule oral treatments.

Our commitment to providing access to high-quality differentiated products while simultaneously navigating manufacturing complexities reinforces Adalvo's position as a trusted leader in the pharmaceutical industry.